These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 29183182)

  • 1. Cost effectiveness of human papilloma virus vaccination in low and middle income countries: a systematic review of literature.
    Silas OA; Achenbach CJ; Murphy RL; Hou L; Sagay SA; Banwat E; Adoga AA; Musa J; French DD
    Expert Rev Vaccines; 2018 Jan; 17(1):91-98. PubMed ID: 29183182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia.
    Berkhof J; Bogaards JA; Demirel E; Diaz M; Sharma M; Kim JJ
    Vaccine; 2013 Dec; 31 Suppl 7():H71-9. PubMed ID: 24332299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Model-based impact and cost-effectiveness of cervical cancer prevention in the Extended Middle East and North Africa (EMENA).
    Kim JJ; Sharma M; O'Shea M; Sweet S; Diaz M; Sancho-Garnier H; Seoud M
    Vaccine; 2013 Dec; 31 Suppl 6():G65-77. PubMed ID: 24331822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study.
    Jit M; Brisson M; Portnoy A; Hutubessy R
    Lancet Glob Health; 2014 Jul; 2(7):e406-14. PubMed ID: 25103394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
    Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB
    Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis.
    Drolet M; Laprise JF; Martin D; Jit M; Bénard É; Gingras G; Boily MC; Alary M; Baussano I; Hutubessy R; Brisson M
    Lancet Infect Dis; 2021 Nov; 21(11):1598-1610. PubMed ID: 34245682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness Analysis of Human Papillomavirus Vaccination in Adolescent Girls in Taiwan.
    Tang CH; Cheng WF; Jiang JH; You SL; Huang LW; Hsieh JY; Mukherjee P; Van Kriekinge G; Lee C
    Asian Pac J Cancer Prev; 2019 May; 20(5):1377-1387. PubMed ID: 31127896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenges in Cost-Effectiveness Analysis Modelling of HPV Vaccines in Low- and Middle-Income Countries: A Systematic Review and Practice Recommendations.
    Ekwunife OI; O'Mahony JF; Gerber Grote A; Mosch C; Paeck T; Lhachimi SK
    Pharmacoeconomics; 2017 Jan; 35(1):65-82. PubMed ID: 27637758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
    Demarteau N; Van Kriekinge G; Simon P
    Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of introducing universal human papillomavirus vaccination of girls aged 11 years into the National Immunization Program in Brazil.
    Novaes HM; de Soárez PC; Silva GA; Ayres A; Itria A; Rama CH; Sartori AM; Clark AD; Resch S
    Vaccine; 2015 May; 33 Suppl 1():A135-42. PubMed ID: 25919154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.
    Gomez JA; Lepetic A; Demarteau N
    BMC Public Health; 2014 Nov; 14():1222. PubMed ID: 25424716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: a systematic review.
    Fesenfeld M; Hutubessy R; Jit M
    Vaccine; 2013 Aug; 31(37):3786-804. PubMed ID: 23830973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors Influencing the Cost-Effectiveness Outcomes of HPV Vaccination and Screening Interventions in Low-to-Middle-Income Countries (LMICs): A Systematic Review.
    Okeah BO; Ridyard CH
    Appl Health Econ Health Policy; 2020 Oct; 18(5):641-654. PubMed ID: 32468410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cost-utility analysis of cervical cancer screening and human papillomavirus vaccination in the Philippines.
    Guerrero AM; Genuino AJ; Santillan M; Praditsitthikorn N; Chantarastapornchit V; Teerawattananon Y; Alejandria M; Toral JA
    BMC Public Health; 2015 Jul; 15():730. PubMed ID: 26223975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The health-economic studies of HPV vaccination in Southeast Asian countries: a systematic review.
    Setiawan D; Oktora MP; Hutubessy R; Riewpaiboon A; Postma MJ
    Expert Rev Vaccines; 2017 Sep; 16(9):933-943. PubMed ID: 28730914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cost-effectiveness of HPV vaccination in addition to screening: a Dutch perspective.
    Setiawan D; Luttjeboer J; Westra TA; Wilschut JC; Suwantika AA; Daemen T; Atthobari J; Wilffert B; Postma MJ
    Expert Rev Vaccines; 2015 Apr; 14(4):589-604. PubMed ID: 25482311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of two-dose human papillomavirus vaccination in Singapore.
    Tay SK; Lee BW; Sohn WY; Lee IH; Mathur G; Sanicas M; Van Kriekinge G
    Singapore Med J; 2018 Jul; 59(7):370-382. PubMed ID: 28983579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of Human Papilloma Virus (HPV) vaccination in Nigeria: a decision analysis using pragmatic parameter estimates for cost and programme coverage.
    Ekwunife OI; Lhachimi SK
    BMC Health Serv Res; 2017 Dec; 17(1):815. PubMed ID: 29216880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human papillomavirus vaccine introduction in low-income and middle-income countries: guidance on the use of cost-effectiveness models.
    Jit M; Demarteau N; Elbasha E; Ginsberg G; Kim J; Praditsitthikorn N; Sinanovic E; Hutubessy R
    BMC Med; 2011 May; 9():54. PubMed ID: 21569406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact and Cost-Effectiveness of Human Papillomavirus Vaccination Campaigns.
    Portnoy A; Campos NG; Sy S; Burger EA; Cohen J; Regan C; Kim JJ
    Cancer Epidemiol Biomarkers Prev; 2020 Jan; 29(1):22-30. PubMed ID: 31666282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.